# Effect of Honey For CIN II

> **NCT06219018** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zuyderland Medisch Centrum** · enrollment: 60 (estimated)

## Conditions studied

- Cervical Intraepithelial Neoplasia-II
- High Risk Human Papillomavirus

## Interventions

- **DRUG:** Medical grade honey formulation (MGH) (L-Mesitran®)

## Key facts

- **NCT ID:** NCT06219018
- **Lead sponsor:** Zuyderland Medisch Centrum
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06219018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06219018, "Effect of Honey For CIN II". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06219018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*